Press release: Uppsala,
Dicot's phase 1 study, aiming at investigating the safety profile in humans, started in
In
The MAD includes some 25 participants divided into different dose groups where the dosage is increased between the different groups. Dicot has now recruited the last participant, which means that the study is progressing according to plan. Overall results are expected to be announced in the second quarter of 2024, as previously communicated by the company.
"The fact that the last MAD participant has been enrolled and that the recruitment for the entire study now is completed is another important milestone that we can tick off. Our collaboration with the CRO partner CTC is exemplary, greatly assisting us in constantly being on schedule", comments Dicot's CEO
For further information, please contact:
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
https://news.cision.com/dicot-ab--publ-/r/recruitment-completed-in-dicot-s-phase-1-trial,c3943515
https://mb.cision.com/Main/17172/3943515/2659335.pdf
(c) 2024 Cision. All rights reserved., source